Nuwellis, Inc. reported its financial results for the third quarter of 2026, highlighting a 24% improvement in operating loss and a notable expansion in gross margins. The company, which focuses on providing solutions for patients with cardiorenal conditions, is seeing positive momentum in its business strategy.
On November 12, 2026, the company released its earnings for the three and nine months ended September 30, 2026. This update is significant as it reflects Nuwellis' efforts to enhance operational efficiency and expand its market presence in the electromedical and electrotherapeutic apparatus industry.
Background
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company based in Eden Prairie, Minnesota. It is classified under the Standard Industrial Classification (SIC) code 3845, which pertains to electromedical and electrotherapeutic apparatus. The company has undergone several name changes, previously known as CHF Solutions, Inc. and Sunshine Heart, Inc. Nuwellis is categorized as a smaller reporting company and a non-accelerated filer.
What the Filing Says
The filing indicates that Nuwellis achieved a gross margin of 69.5% in the third quarter, up from 65.2% in the same period last year. The company reported an operating loss of $2.1 million, which is a 24% improvement year-over-year. Additionally, net sales for the third quarter were $2.2 million, remaining stable compared to the prior year, but showing a 12% sequential increase.
In the press release attached to the filing, Nuwellis noted, "We have made meaningful progress in strengthening Nuwellis both commercially and financially." The company also emphasized its growth in the pediatric segment, with net sales increasing by 20% in the third quarter compared to the previous year.
Impact
This financial update may influence various stakeholders, including investors, healthcare providers, and competitors. The improved operating loss and margin expansion indicate a more robust financial health for Nuwellis, which could attract further investment and interest from healthcare professionals looking for effective solutions for cardiorenal conditions.
What's Next
The filing does not specify what happens next, but Nuwellis has indicated ongoing efforts to expand its product offerings and improve its market presence. The company is also expected to conduct a conference call to discuss these results further.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










